7/6/2023 | BK | Myriad Genetics secures revolving facility for initial $90 million
|
7/27/2022 | BK | Myriad Genetics reduces revolver to $200 million, waives covenants
|
8/1/2018 | BK | Myriad ups revolver commitments to $350 million for Counsyl purchase
|
12/28/2016 | BK | Myriad Genetics obtains $300 million five-year revolving facility
|
9/1/2016 | BK | Myriad borrows $200 million of term loans to fund Assurex purchase
|
8/4/2016 | BK | Myriad Genetics plans new debt financing for Assurex purchase
|
5/11/2010 | SP | Barclays to price 9% reverse convertibles linked to Myriad Genetics
|
4/12/2010 | SP | Barclays to price 10.25% reverse convertibles linked to Myriad Genetics
|
3/25/2009 | SS | Market Commentary: No second bids expected for Petro-Canada; Myriad stock predicted to hit $91 after spinoff
|
11/8/2006 | BT | Myriad kept at buy by Merrill
|
11/7/2006 | BT | Myriad Genetics reports increased revenue, profits, from molecular diagnostic business
|
11/7/2006 | BT | JMP keeps Myriad at strong buy rating
|
9/14/2006 | BT | Merrill maintains Myriad at buy
|
9/8/2006 | BT | JMP cites a positive view of genetics, breast cancer
|
8/23/2006 | BT | Myriad Genetics reiterated at strong buy by JMP
|
8/22/2006 | BT | Myriad Genetics reiterated at strong buy by JMP
|
8/22/2006 | BT | Merrill reiterates Myriad at buy
|
8/22/2006 | BT | Myriad says cash from current products funding development programs; posts $11.4 million Q4 net loss
|
8/22/2006 | BT | Myriad Genetics completes enrollment in Flurizan trial for Alzheimer's disease
|
8/1/2006 | BT | Myriad debuts breast cancer diagnostic test for high-risk patients
|
7/20/2006 | BT | Myriad Genetics reiterated at strong buy by JMP
|
7/19/2006 | BT | Merrill maintains Myriad at buy
|
7/19/2006 | BT | Myriad says Flurizan study demonstrates significant benefit in Alzheimer's disease patients
|
5/3/2006 | BT | Merrill maintains Myriad at buy
|
5/3/2006 | BT | Myriad reiterated at strong buy by JMP
|
5/2/2006 | BT | Myriad Genetics at strong buy rating from JMP
|
5/2/2006 | BT | Market Commentary: Vical top pick in bird flu flock; Noven sinks on profit taking; NitroMed dives, Myriad higher
|
5/2/2006 | BT | Myriad Genetics begins phase 1 trial of anti-thrombin drug MPC-0920
|
4/11/2006 | BT | Myriad, Abbott to collaborate on drug discovery
|
3/22/2006 | BT | Myriad reiterated at buy by JMP
|
3/22/2006 | BT | Merrill maintains Myriad at buy
|
3/13/2006 | BT | Myriad Genetics at strong buy by JMP
|
3/13/2006 | BT | Market Commentary: NitroMed off on data; NPS gains 7%; Vasogen falls on trial failure; Medicines up 10%; Myriad higher
|
3/13/2006 | BT | Myriad follow-on study of Flurizan demonstrates continued benefit in Alzheimer's disease
|
3/13/2006 | BT | Merrill maintains Myriad Genetics at buy
|
2/27/2006 | BT | Merrill puts Myriad at buy
|
2/9/2006 | BT | JMP moves Myriad Genetics to strong buy
|
2/7/2006 | BT | Myriad reiterated at market outperform by JMP
|
2/7/2006 | BT | Myriad Genetics sees three drugs advancing, two new clinical trials in 2006
|
11/16/2005 | BT | JMP reiterates Myriad at market outperform
|
11/16/2005 | BT | Myriad maintained at buy by Merrill Lynch
|
11/15/2005 | BT | Myriad says follow-on phase 2 study shows Flurizan improves cognitive ability in Alzheimer's patients
|
11/8/2005 | BT | Myriad Genetics greenshoe exercised, raising follow-on offering to $148.9 million
|
11/4/2005 | BT | Market Commentary: Introgen's stock lifts on Colgate-Palmolive alliance; Cytori, Olympus enter into joint venture
|
11/3/2005 | BT | New Issue: Myriad Genetics prices $129.5 million follow-on offering at $18.50 per share
|
11/3/2005 | BT | Market Commentary: Abgenix, Amgen stocks take off on successful phase III study; Merck wins legal battle over Vioxx
|
11/2/2005 | BT | Market Commentary: Novavax stock slips 12.3% on $18 million direct placement; convertible biotech names mixed
|
10/31/2005 | BT | Market Commentary: NeoPharma skyrockets on new CEO; Charles River Labs higher; Nabi, Indevus, Invitrogen up
|
10/28/2005 | BT | Myriad Genetics plans follow-on sale of 7 million shares via JP Morgan
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
10/27/2005 | BT | JMP keeps Myriad at market outperform
|
10/26/2005 | BT | Merrill maintains Myriad buy rating
|
10/18/2005 | BT | Myriad Genetics publishes depression gene discovery in Molecular Psychiatry
|
10/3/2005 | BT | Amylin sales looking up as Biogen may face downside, Merrill report says
|
9/23/2005 | BT | Myriad maintained by JMP at market outperform
|
9/23/2005 | BT | Myriad maintained by Merrill Lynch at buy
|
9/16/2005 | BT | Myriad initiated by Rodman & Renshaw at market outperform
|
8/24/2005 | BT | Myriad kept by JMP at market outperform
|
8/24/2005 | BT | Myriad upgraded by Merrill Lynch to buy
|
8/2/2005 | BT | Myriad Genetics kept by Merrill at neutral
|
8/2/2005 | BT | Myriad kept by JMP at market outperform
|
7/14/2005 | BT | Myriad Genetics initiated by Merrill at neutral
|
4/7/2005 | CV | Myriad Genetics files $300 million shelf
|